



GlaxoSmithKline

February 6, 2012

The Manager - Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra-Kurla Complex
Bandra (East), Mumbai - 400 051

GlaxoSmithKline
Consumer Healthcare Ltd.

DLF Plaza Tower
DLF City Phase-1
Gurgaon 122002
Haryana, India

Tel. (0124) 2540700 / 4057700
Fax. (0124) 2540720-21
www.gsk.com

Dear Sir,

Subject: Audited Financial Results for the year ended December 31, 2011, intimation of the Book Closure dates, Date of dividend payment, Annual General Meeting and Appointment of Mr. Jaiboy Phillips as a Wholetime Director of the Company

Pursuant to the applicable clauses of the Listing Agreement, please note that the Board of Directors of the Company at its meeting held on February 6, 2012, has approved the Audited Financial results for the year ended December 31, 2011, a copy of which is enclosed for your reference and records.

The Board also recommended a Dividend at the rate of Rs. 35/- per equity share of Rs. 10 each. The dividend, if approved by the shareholders in the ensuing Annual General Meeting scheduled to be held on March 22, 2012, will be paid to those members whose names appear in the Company's Register of Members and to those persons whose names appear as Beneficial owners as per the details to be furnished by National Securities Depository Limited and Central Depository Services (India) Ltd. as at the close of business hours on March 12, 2012. The dividend shall be paid to the entitled Members on or before April 3, 2012.

The Register of Members and Share Transfer Books will remain closed from March 13, 2012 to March 22, 2012, both days inclusive, for the purpose of Dividend and Annual General Meeting.

The 53rd Annual General Meeting of the members of the Company will be held on Thursday, March 22, 2012 at 9.30 a.m. at Punjab Public School Auditorium, The Punjab Public School (Senior Wing), Nabha 147 201 (Punjab).

The Board had also appointed Mr. Jaiboy John Phillips as a Wholetime Director of the Company, w.e.f. 6 February 2012, in the casual vacancy caused by the resignation of Mr. Praveen K Gupta, Director – Operations.

Kindly take the above intimation on your records.

Thanking You

Yours faithfully
for GlaxoSmithKline
Consumer Healthcare Limited

Surinder Kumar
Executive Vice President – Legal &
Company Secretary

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED
AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2011

(Rs. in Lakhs)

PARTICULARS	QUARTER ENDED (UNAUDITED)			YEAR ENDED (AUDITED)	
	Dec 31, 2011	Sep 30, 2011	Dec 31, 2010	Dec 31, 2011	Dec 31, 2010
1. (a) Net Sales / Income from Operations	6,02,05	7,20,07	5,07,76	26,85,51	23,06,12
(b) Other Operating Income	22,74	24,53	16,43	85,17	67,63
Total Income	6,24,79	7,44,60	5,24,19	27,70,68	23,73,75
2. Expenditure:					
a) (Increase)/Decrease in Stock in Trade and Work in Progress	(72,34)	(5,38)	(53,96)	(44,00)	(29,80)
b) Consumption of Raw Materials	1,94,32	1,80,75	1,44,73	7,00,62	5,85,21
c) Consumption of Packing Materials	61,12	64,99	52,20	2,31,79	1,93,13
d) Purchase of traded goods	31,03	32,55	35,40	1,34,33	1,16,37
e) Employee's Cost	61,70	66,27	60,89	2,58,37	2,29,66
f) Advertising & Promotion	1,14,16	1,19,62	89,45	4,37,34	3,70,63
g) Depreciation / Amortisation	12,09	11,65	10,90	45,98	39,71
h) Other Expenditure	1,50,43	1,43,27	1,20,63	5,42,10	4,64,20
i) Total Expenditure (a+b+c+d+e+f+g+h)	5,52,51	6,13,72	4,60,24	23,06,53	19,69,11
3. Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	72,28	1,30,88	63,95	4,64,15	4,04,64
4. Other Income	25,91	23,11	16,71	79,58	49,76
5. Profit before Interest & Exceptional Items (3+4)	98,19	1,53,99	80,66	5,43,73	4,54,40
6. Interest	88	1,03	68	3,47	2,60
7. Profit after Interest but before Exceptional Items (5-6)	97,31	1,52,96	79,98	5,40,26	4,51,80
8. Exceptional Items	-	-	-	-	-
9. Profit (+) / Loss (-) from Ordinary Activities Before Tax (7+8)	97,31	1,52,96	79,98	5,40,26	4,51,80
10. Tax expense	38,21	49,93	26,61	1,85,05	1,51,95
11. Net Profit (+) / Loss (-) from Ordinary Activities after Tax (9-10)	59,10	1,03,03	53,37	3,55,21	2,99,85
12. Extraordinary Items (net of tax expense)	-	-	-	-	-
13. Net Profit (+) / Loss (-) for the period (11-12)	59,10	1,03,03	53,37	3,55,21	2,99,85
14. Paid Up Equity Share Capital	42,06	42,06	42,06	42,06	42,06
- Face Value of Equity Shares-Rs.	10	10	10	10	10
15. Reserves excluding Revaluation Reserves as per Balance Sheet of the previous accounting year					
16. Earnings Per Share (EPS) - Rs.					
(a) Basic and diluted EPS before Extraordinary items for the period and for the previous year (not annualized)	14.05	24.50	12.69	84.46	71.30
(b) Basic and diluted EPS after Extraordinary items for the period and for the previous year (not annualized)	14.05	24.50	12.69	84.46	71.30
17. Public Shareholding					
- Number of Shares	2,39,03,295	2,39,03,295	2,39,03,295	2,39,03,295	2,39,03,295
- Percentage of Shareholding	56.84	56.84	56.84	56.84	56.84
18. Promoters and Promoter Group Shareholding					
a) Pledged/Encumbered					
- Number of shares	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
b) Non-encumbered					
- Number of shares	1,81,52,243	1,81,52,243	1,81,52,243	1,81,52,243	1,81,52,243
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00
- Percentage of shares (as a % of the total share capital of the Company)	43.16	43.16	43.16	43.16	43.16



NOTES

(1)

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED		
AUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT YEAR ENDED DECEMBER 31, 2011		
	(Rs in Lakhs)	
	As at Dec 31, 2011	As at Dec 31, 2010
SHAREHOLDERS' FUNDS		
(a) Capital	42,06	42,06
(b) Reserves and Surplus	11,02,12	9,17,98
LOAN FUNDS	-	-
TOTAL	11,44,18	9,60,04
FIXED ASSETS #	3,71,76	3,10,58
INVESTMENTS	-	0
DEFERRED TAX ASSET (net)	39,89	26,73
CURRENT ASSETS, LOANS AND ADVANCES		
(a) Inventories	3,69,96	3,12,00
(b) Sundry Debtors	99,19	50,37
(c.) Cash and Bank Balances	10,79,65	9,76,10
(d) Other Current Assets	49,16	34,56
(e) Loans and Advances	72,14	50,11
Less: CURRENT LIABILITIES AND PROVISIONS		
(a) Current Liabilities	6,66,32	4,70,37
(b) Provisions	2,71,25	3,30,04
MISCELLANEOUS EXPENDITURE (Not written off adjusted)	-	-
PROFIT AND LOSS ACCOUNT	-	-
TOTAL	11,44,18	9,60,04

Fixed Assets includes CWIP & Capital Advances aggregating Rs 1,71,07 Lakhs as at Dec 31, 2011 (Rs 1,08,33 Lakhs as at Dec 31, 2010)



GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2011

NOTES

- (2) The Company's nutritional business is India focused and in a single business and geographical segment. Accordingly segment information is not applicable.
- (3) The Company received 33 investor complaints during the quarter ended December 31, 2011 which were duly resolved by the end of the quarter. There were no investor complaints pending at the beginning and at the end of the quarter.
- (4) The Board of Directors has recommended a Dividend of Rs. 35/- per Equity share of Rs. 10 each , for the year ended December 31, 2011, at its meeting held on February 6, 2012. The Dividend, if approved by the Members at the ensuing Annual General Meeting to be held on March 22, 2012, will be paid on or before April 3 ,2012 to those Members whose names appear in the Company's Register of Members as on March 12,2012.
- (5) The above results and this release have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at its meeting held on February 6, 2012.
- (6) The figures of the last quarter are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year
- (7) Figures for the previous period have been regrouped/reclassified wherever necessary, to conform to the current period's classification.

REGD. OFFICE:PATIALA ROAD, NABHA 147201 (PUNJAB).
HEAD OFFICE:DLF PLAZA TOWER, DLF CITY PHASE I,
GURGAON - 122002, HARYANA.

GURGAON
February 6, 2012



ON BEHALF OF THE BOARD

A handwritten signature in blue ink, appearing to read "Zubair Ahmed", written over a horizontal line.

ZUBAIR AHMED
MANAGING DIRECTOR

The Board of Directors
M/s. GlaxoSmithKline Consumer Healthcare Limited
Patiala Road,
Nabha – 147201
Punjab

1. This report is produced in accordance with the terms of our agreement dated January 30, 2012.
2. We have audited the accompanying 'Audited Financial Results for the year ended December 31, 2011' (the 'Statement') of GlaxoSmithKline Consumer Healthcare Limited (the "Company"), prepared by the Company's directors pursuant to the requirement of Clause 41 of the Listing Agreement, in which are included its annual financial results for the year ended December 31, 2011 and the statement of assets and liabilities as on December 31, 2011, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which we have traced from disclosures made by the Management and accordingly, have not been audited by us. As mentioned in Note 6 to the Statement, the figures for the quarter ended December 31, 2011 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures, subjected to limited review, up to the third quarter of the current financial year.

Directors' Responsibilities

3. The directors of the Company are responsible for preparing the Statement that gives a true and fair view of the net profit and other financial information for the year ended December 31, 2011, and also the statement of assets and liabilities as at December 31, 2011.
4. The directors have prepared the Statement on the basis of the Company's annual financial statements, prepared in accordance with the accounting standards issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other accounting principles generally accepted in India, in compliance with the requirement of Clause 41 of the Listing Agreement.
5. The responsibility of the directors include the design, implementation and maintenance of internal control relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibilities

6. Our responsibility is to express an opinion on the Statement based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.
7. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by Management, as well as evaluating the overall presentation of the Statement.




8. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

9. In our opinion, and to the best of our information and according to the explanations given to us, the Statement:
- (i) is presented in accordance with the requirements of Clause 41 of the Listing Agreement in this regard; and
 - (ii) gives a true and fair view of the net profit and other financial information for the year ended December 31, 2011 and also gives a true and fair view of the statement of assets and liabilities as at December 31, 2011.
10. Further, we also report that we have traced the number of shares as well as the percentage of shareholdings in respect of the aggregate amount of public shareholdings, as well as that of the promoters and promoter group (both pledged/ encumbered and non-encumbered), as disclosed in terms of Clause 35 of the Listing Agreement, from the representations and other records and information and explanations given to us by the Company's Management, and found the same to be in accordance therewith.

For Price Waterhouse
Firm Registration Number: 301112E
Chartered Accountants



Usha Rajeev
Partner
Membership Number: F 087191

Place: Gurgaon
Date: February 6, 2012